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Objectives. The purpose of this sfody WPI to elucidate whether 
the effectiveness of long&rm beta-blocker tkeropy could be 
predicted before this therapy is started, 
&&round, Long-term bfia.blwkw therapy has recently 
two reported to provide a favorabte elftct in treatment of 
congestive heart failure doe to dilated cardiomyopathy. 
hfefhads Several measuremrnb lwluding hiitotogic vnrlable~ 
before adndnisiration of metoproto! were retrosptctiwly corn- 
pared among 18 good reponderp @&wing improvement of at 
least one New York Heart Asvclation fooctiinal class or P” 
iocrta* in ejection fradion >O.lO 12 monlha atIer drug admtn- 
istratton) and 12 poor respandsrs without such improvement. 
Restd~~. Although there were no sit@icant dltfereaeps between 
the two groups in ago, gender, fundionid class, heart rate, blood 
pressure, pulmonary capttlnry wed@ 9rew.o1?, eardlac Index, left 
ventricular end.dkstottc dimension and ejectIon fiwtton, percent 
fibrosis estimated by the point-counting method in andomyoear- 
dial blqtsyspeeimens was signiftcantly lower in good thnn in pew 
resfwndtrs (7.6 t 5.7 vs. 14.2 t 9.7%, p < 0.05). Moreover. 
when the types of fibrosis were chwiified as tnterfas&alar and 
intercettulnr by tbe dominance of counted points, Iherc wn 13 
cases of interfas&olar fibrosis and g cases al inttrcethdar fibrusts 
in gocd resm and I case of lnterfticutar fibrods and 11 
cases of lnttrrrllulsr fibrosis to poor respcnden (p < 0,001, 
wosititity 72% spechlcity 91% predktiveaceoracy 80%). These 
resulta sogbcst that improvement with Irmg-term beta-bkder 
therapy may be more tttcty to weor to pattents with ku mywar- 
din1 fibrosis, rtih tnttrfa?&utar fibrosis the domtnrmt type. 
Conc/wionr. The extent and typeof6brmic may be important 
factors in the predktian of the effectiwmss of tong-term beta- 
btoeker therapy fw dilated card&myopathy. 
(J Am Co11 Gudiol1993;21:628-33) 
unsl;ar which subgroup of patients with dilated cardiomy- 
opathy would be likely to benefit from long-term heta- 
The purpose of this study was to elucidate whether the 
ebctiveness of long-term beta-blockade could be predicted 
from a variety of data, including histologic find&. before 
this therapy was begun in patients with dilated cardiomyop- 
Dilated cardiomyopathy is a heart muscle disease character- 
ized by left ventricular dilation and impaired contraction of 
unknown cause, resulting in a poor prognosis. Several blocker therapy. 
investigators (I-l I) recently reported that long-term beta- 
blocker therapy could provide a favorable effect in treatment 
of congestive heart failure due to dilated cardiomyopathy. In 
these studies, it was shown that long-term beta-blocker 
therapy improved New York Heart Association functional athy. 
class, exercise capacity (l,2), hemodynamic state (3-6) and 
survival rate (7-9), and that withdrawat of betambfocking 
agents produced a deleterious effect (l&11). These results Methods 
revealed the usefulness of long-term beta-blocker therapy in 
rtients with dilated cardiomyopathy. However, there was a 
subgroup of patients with dilated cardiomyopathy who did 
not respond to the beta-blocker therapy (9,ll). It remains 
Patient sehxtlon. The study group consisted of 30 pa. 
tients with dilated cardiomyopathy who experienced at least 
one episode of decompensated heart failure. These 30 pa- 
tients of a consecutive series of 63 patients with dilated 
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cardiomyopathy in our previous randomized controlled 
study (4~5.12) had been followed up as the group with the 
administration of a beta-blocker. Dilated cardiomyopathy 
was diagnosed by echocardiography, coronary angiography 
and endomyocardial biopsy, according to the criteria pro- 
posed by the World Health Organizatiotintemational Soci- 
ety and Federation of Cardiology Task Force (13). No 
patient had coronary artery disease (>25% diameter reduc- 
tion of a major coronary vessel). Of the 30 study patients. IO 
had minor arteriosclerosis with 525% lumen stenohis. In all 
patients, acute or chronic myocardilis was excluded by the 
finding at endomyocardial biopsy. Other causes of cardio- 
myopathy were also excluded. Subjects were enrolled during 
the stable stage of the disease aFter conventional treatment 
with digitalis and diuretic drugs for z I month. The mean age 
of the patients was 58 years (range 21 to 72); there were I9 
men and II women. The mean interval from the onset of 
symptoms to enrollment was 31 months (range 2 to 120). 
Measurements before the administration of a beta~hlacking 
agent. Before the administniion of a beta-blocking agent. 
all patients underwent echocardiography, cardiac catheter- 
ization and I& ventricular endomyocardial biopsy. 
Echoca&~gmnph~. Two-dimensional echocardiography 
was perlormed with a Toshiba SSH-65A or 16OA recorder 
equipped with 2.S- or 3.75.MHz transducer. The standard 
technique (14) was employed for sizing the left ventricle. 
Left ventricular dimensions were measured at end-diastole 
on the R wave ofthe electrocardiogram (ECG)_derivcd QRS 
complex and at end-systole just below the level of the mitral 
leallets through the standard left parasremal window. The 
transducer position was aided by the cross-sectional 
echocardiographic analysis. Left ventricular ejection fnc- 
lion was calculated by the method of Gibson (15). 
Cardiac catheterization. A Swan-Ganz thermodilution 
catherer was introduced through the right subclavian vein 
Figure 1. Representative types of fibrosis in patients wilh dilated 
cardiomyopalhy. Left, Dominanr interfascicular lype of hbmsis in 
which rhe fibrous tissue is relarively localized and more fibmus 
tissue lies in the haerfascicular space than the intercellular space. 
Ri@i, Dominant intercellular type of fibmsis in which the diffuse 
tibmus tissue mainly encircles and separates individual muscle 
fibers. 
and poshioned in the pulmonary artery. Heart rate. systemic 
blwd pressure and pulmonary wedge pressure were mea- 
sured. Cardiac output was determined by the thcrmodilution 
technique. 
E&NI_KJ ~rr&l biopsy. In each patient, at least three 
endamyocardial biopsy samples were &en fmm the free 
wall of Ihe left ventricle, using an Olympus bioptome and a 
6F long sheath inserted from femoral artery into left venlri- 
cle. The average weight of the specimens was 2.72 * 
0.24 mg. All samples were used for point counting according 
to the method of Weibel et al. (16) after Alan-Msllory 
staining. Cross points falling on fibrosis, excluding endocar- 
dial fibrosis, as well as that on myocytes in the magaifled 
picture (X40). were counted by two independent microsco- 
pists who had no knowledge of clinical data. The total 
count was 882 ? 140 in each patient. The volume fraction of 
fibrous tissue was obtained as percent fibrosis, which was 
calculated by dividing the count of cross points falling on 
fibrosis by the total count. Furthermore, the dominant type 
of fibrosis was classified as intercellular or interfascicular by 
Figure 2. Echocardiographic changes in gwd and 
poor responders with dilated cardiomyopathy to 
lo?.:-term beta-blocker therapy. Data are mean val- 
ucs i SD. Good responders (hat&d ban1 had 
improvement of at leasl one New York Heart Assc- 
ciation functional class or an increase in eiection 
fraction ~0.10, whereas none of the poor res&nden 
(own bars1 had such imoravement. Note that there 
w&e no significant diff&nces in ejection fraction 
(EF), left ventricular end-diastolic dimension 
(LVDd) or left ventricular end-systolic dimension 
(LVDa) between good and poor responders before 
the start of beta-blocker therapy. 
the dominancy of the counted points of each fibrosis. Inter- 
cellular and interfascicular fibrous tissues were determined 
respectively, according to the report of Anderson et al. (17) 
on histopathologic types of myocardial fibrosis (Fig. 1). 
lntercelhdar fibrous tissue encircled and separated individ- 
ual fibers so that every muscle fiber in the affected area 
would be ensheathed. In contrast, interfascicular fibrous 
tissue was associated with coflagenous tissue to the a&en- 
titia of peripheral vessels. These vessels lay between groups 
of myocardial fibers so that interfascicular fibrous tissue 
delineated groups of m&s& tibers into bundles or fascicles. 
Drug protocol. Metoprofot was administered at an initial 
dose of 5 to 10 mgiday. The dose was increased in stepwise 
increments by 5 to 20 mglday over an interval of 2 to 8 
weeks, taking care of deterioration of heart failure up to the 
therapeutic final dose of 60 mglday unless severe hypoten- 
sion (~80 mm Ng), bradycardia (~40 beatsimin) or any signs 
of clinical decompensation appeared. During the follow-up 
period, the dose of other drugs for heart failure remained 
unchanged and neither angiotensin-converting enzyme in- 
hibitors or calcium channel antagonists were administered. 
Evaluation of the effectiveness of long.term beta.blorker 
therapy. The effectiveness of long-term beta-blocker ther- 
apy was assessed again by echocardiography 12 months after 
the administration of metoprolol, because improvement was 
shown to be a slow process that takes from 3 to I2 months in 
our and other previous studies (4.5.1 I). According to the 
degree of improvement in functional class and left ventricu- 
lar ejection fraction, patients were classified into two groups: 
good responders with improvement of at least one functional 
class or increase in ejeciion fraction of 80.10 and mr 
responders without such improvement with long-term beta- 
blocker therapy. 
Statistical analysis. Results were expressed as mean 
value + SD. A two-factor repeated measures analysis of 
variance was used for paired data (comparison of echocar- 
diographic data between before and 12 months after beta- 
blocker therapy) and unpaired data (comparisons between 
good and poor responders). The relation between the re- 
sponse to long-term bela-blocker therapy and the dominant 
rype of fibrosis was examined with a cbi-square test. A p 
value < 0.05 was considered significant. 
Results 
Response to lon@erm beta-blocker therapy. No patients 
showed deterioration of congestive heart failure as a result of 
metoprolol administration. Fourteen patients had both 
symptomatic and objective improvement. In contrast, the 
other I2 patients had neither symptomatic nor objective 
improvement. The remaining four patients had improvement 
of one functional class without an increase in ejection 
fraction 20. IO. Accordingly, 18 oi 30 patients with dilated 
cardiomyopathy had a good response to long-term beta- 
blocker therapy, whereas the remaining I2 patients had a 
poor response. Ail but three patients received the final 
therapeutic dose of M) mg/day of metoprolol. These three 
patients (one good responder and two poor responders) 
received a dose of 40 mdday. There was no significant 
diierence in the final dose of metoprolol between good and 
poor responders. Figure 2 shows eehocardiographic changes 
12 months after the start of beta-blocker therapy in good and 
poor responders. In good responders, left ventricular end- 
diastolic (62.7 + 6.1 to 59.3 f 5.5 mm, p < 0.005) and 
end-systolic (52.5 3- 7.1 to 43.0 2 7.1 mm, p < O.ooOl) 
dimensions significantly decreased and ejection fraction 
markedly increased (0.40s i: 0.067 lo 0.538 -c 0.087, p < 
0.0001). Conversely, in poor responders, there were no 
significant changes in left ventricular dimension or ejection 
fraction. 
Comparison of baseline data in good and poor responders 
(Table I). There were no significant differences between 
good and poor responders at entry in terms ofthe following: 
age, gender, functional class, hemodynamic variables such 
as heart rate, systemic blood pressure, pulmonary capillary 
wedge pressure, cardiac index and left ventricular end- 
diastolic, end-systolic dimensions and ejection fraction (Fig. 
21. 
Table 1. Baseline Dala at Study Enlry Frum Good and Poor 
Responders to Long-Term Bela-Blocker Therapy 
Gorvl Rcrnonderr Poor Rcroondcr, 
significantly lower than that in poor responders (7.6 2 i.7B 
Comparison of histologic findingv in grind aad pnnor re- 
spenders (Table 2). Percent fibrosis in good responders was 
vs. 14.2 f 9.7%. p < O.Ojl. Table 2 shows the relation 
call\ IO long-icon beta-blocker therapy. with symptomatic 
and functional improvement and prolonged life. Therefore. it 
II was repo&l’(l.SjthaI the tolerance to beta-blockers in 
is important ro identify the characteristics that distinguish 
those patients who will benefit from long-term beta-bIocker 
dilated cardiomyopathy might be af least partially predicted 
thrrapy front Those whom it will not benelit. 
ldeotification ofgood respouders to Ioug&-m beta-blocker 
Iherapy. Some investigators (I .2,18) reported that the most 
favorable r sponse occurs in patients with a higher heart rate 
at rezt 2nd more advanced left venbicular dysfuncrion. 
However. in the present study. heart rate, blood pressure. 
pulmonary capillary wedge pressure. cardiac index or 
tchocardiographic variables of cardiac function did not help 
predict improvement with long-term beta-blocker therapy. It 
was also reponed 119) that hemudynamic variables before 
the administration of a beta-blocker did not predict the 
clinical rcspome to the drug. Thus. the clinical significance 
of hemodynamic variables for predicziog th.2 effectiveness of 
beta-blocker therapy remains controversial in patients with 
dilated cardiomvouathv. 
between the dominant fibrosis type and the effecliveness of by the severity of structural abnormality. which was qoali- 
long-term beta-blocker thenpy. Thirteen of IS good re- ‘rtively estimated from the extent of fibrosis, myocyte 
spenders had dominant inrerfascicular fibrosis and 1 I of I? hypenrophy and nuclear abnormality in endomyocardial 
poor responders had dominant intercellular fibrosis. A sig- bioosv barnohs. In that studv 1181. il was shown that there 
&cant relation was observed between the fibrosis type and 
the effectiveness ofbeta-blocker therapy @hi-square = 11.8, 
p < 0.001). This fibrosis type gave a sensitivity of 72%. a 
specificity of 91% and a predictive accuracy of 80% for 
prediction of the etfectiveness of long-term beta-blocker 
therapy. 
The present study demonstrated that long-term beta- 
blocker therapy would be expected to be more effective in 
patients wirh less myocardial fibrosis, with the dominant 
type of fibrosis being interfa>cic&u rn:her than intercellular 
fibrosis. These results indicate that the extent and type of 
fibrosis in endomyocardial biopsy specimens might be im- 
uortant factors for predicting the effectiveness of lorp- trm 
was a 50%‘chnnce of deter&&n in the presence of the 
most seyere histologic change. whereas most patients with 
mild or moderate abnonualities should tolerate beta-blocker 
therapy. Thus. only tolerance IO bera-blocker thempy was 
discussed in their study (IS). In the present study. we 
demonstnted lhrt histologic findings such as the dominant 
type and extent of fibrosis might be important factors for 
predicting the effectiveness of long-term beta-blocker ther- 
apy in paiients who are able to tolerate the drug. 
Although good responders in this study actually had 
significantly less myocardial fibrosis than that of poor re- 
spenders. some patients wilh a similar extent of fibrosis 
showed various responses IO long-term beta-blockade. It is 
suggested that the extent of fibrosis might not be the only 
variable that explains the difference in the response to 
lone-term beta-blocker theraav. Converselv. it miaht be 
beta-blocker therapy. 
u .~ . _ 
It has been reported (1,2.8,9,11) that a subgroup of 
thought that histologic findings themselves have already 
determined the subsequent clinical course in palients with 
patients with dilated cardiomyopathy responded dramati- dilared cardiomyopathy, itrespective of the administration of 
a beta-blocker. However. in our previous studies 14.51. there 
Table 2. Relation Between the Dominant Type of Myocardial 
was no significant clinical improvement I2 months after 
Fibrosis and the Response to Beta-Blocker Therapy in Patients enrollment in patients without long-term beta-blockade. ir- 
With Dileted Cardiomyopathy respective of rhe dominant type of fibrosis (intercellular 
Datinani Type uf Fibrws 
dominant type: left ventricular end-diastolic dimension 
Respanse 1” aera- All 65.5 i 12.2 to 66 2 12.3 mm. ejectiai. fraction 0.435 f 0.055 
Blacker Therapy lntelfarclcular Intercellular Rlicnlr to 0.45 5 0.11 In = 61: interfascicular dominant tvoe: left 
Good responden II 5 il ventricular end-diastobi dimension 62.7 L 3.4 t6i9.4 + 
Poor responders I II I! 5.9 mm. ejection fraction 0.404 + 0.077 to 0.454 + 0.119 
MI palirnls 14 16 i” [n = 71). Therefore. it is natural to consider that clinical 
p < O.Wl. cbkquare = 11.8 furallvaluer. aslaars erpwed as number improvement in this study was attributed to the administra- 
cfpatientr. tion of metoprolol and that histologic findings such as the 
extent and type of fibrosis could determine the response to 
long-term beta-blocker therapy in patients with dilated car- 
diomyopathy. 
Other factors that might afledihe response to beta-bide 
Iberapy. The interval from the onset of symptoms to enroll- 
ment in this study did not correlate with rhe extent oftibmsis 
(r = 0.102). Furthermore, there was no significant difference 
in this interval between patients with dominance ofinterfas- 
cicular or intercellular fibrosis (30.3 ? 31.2 vs. 32.5 + 31.7 
months). Thus, neither the extent nor the lype of fibrosix was 
related to this time difference. Hnwever. this interval teaded 
to be shorter in good responders rhan in poor responders 
(23.2 1 18.2 to 39.3 1 34.4 months). Therefore. it is 
suggested that the earlier therapy is begun, the n~ore e&c- 
tive it would be in patients with dilated cardiomyopalhy. 
We also performed symptom-limited multistage supine 
bicycle ergometry. monitoring the hemodynamic variables 
with a SwanGanz catheter in 12 study patients. Although 
there was no difference between good and poor responders 
in pulmonary capillary wedge pressure at the end point of the 
exercise test after long-term beta-blcckade (good respond- 
ers, 28.3 ? 14.2 to 29.4 i 11.7 In = 71: poor responders. 
24.6 2 Il.4 to 25.4 t 5.6 mm Hg [n = S]), cardiac index 
tended to mcrease in good responders (5.12 + I. 19 to 5.39 t 
1.91 liters/min per m’), whereas chat in poor responders 
tended IO decrease (5.58 r 1.88 fo 5.27 c 1.98 litersfmin per 
m’). Furthermore, stroke work index at the end of exercise 
tended to increase in good responders after long-term beta- 
blockade (48.5 & 19.5 to S9.1 + 18.7 mm Hpml/mz, p = 
O.W), while that in poor responders tended to decrease 
(74.3 ? 41.0 to 64.6 ? 28.5 mm Hgmlim*). The percent 
improvement in stroke work index was signiftcantly better in 
good responders than in poor responders (32.6 ? 35.2 vs. 
-7.72 ? 18.32, p < 0.05). It is suggested that these exercise 
test data s.upp~T: the reasonableness ofclinical improvement 
with long-term beta-blockade. 
Relation between myoeardial fibrosis and left ventiular 
functinn. Although there was a considerable difference in 
the extent and type of myocarchal fibrosis between good and 
poor responders in this study, there aa$ nn difference in the 
degree of left ventricular functional lmpalrment before the 
initiation of beta-blocker therapy. The finding that the1.e WBY 
no signiRcnnt correlation between the extent of fibrosis and 
left ventricular dysfunction in patients with dilated car& 
myopathy was similar to that in wports in previous enda. 
myacardial biopsy studies (20,21). However, this was no1 
the case in other reports (Z&23). Thus, the relation between 
myocardial fibrosis and l&t ventrcular dysfunction remains 
controversial. 
Catecholamine hypothesis: @ophpialagic consideratton 
of the typesolfibrosis. Plasma cstecholaminc lcvcl is known 
as a major predictive factor ot death in patients with heart 
failure (24). It has been reported (25) that a compensatory 
increase in sympathetic nerve actirity for the failing hean 
will lead to worsening of the failing status by means of 
beta-receptor down regulation and catecholamine-induced 
cardiac toxicity. In the present study, the plasma concemra- 
tion ofnorepinephrine before beta-blocker therapy tended to 
be higher in good than in poor responders (0.66 -t 0.29 [n = 
IO] vs. 0.49 1 0.38 &ml [n = 7]), whereas there was no 
significant difference in beta-receptor density of peripheral 
lymphocytes (I.550 + 980 in = 91 Vs. 1,409 f 343 sites/cell 
[n = 51) between the two groups. It is suggested that 
variables that characterize the adrenergic state might possi- 
bly be useful as a @de to beta-blocker therapy in dilated 
cardiomyopathy. 
The parhoEenesis of interfascicular and intercellular fi- 
brosis remains unknown, although it is reasonable that the 
more extensive the fibrosis, the lesr the improvement in 
cardiac function in terms ofquantity of residual cell volume. 
In the present study. however, plasma concentration of 
norepinephrine in patients with dominant ;ntetiarcicular 
Bbrosis tended to be higher than in those with dominant 
intercellular fibrosis (0.61 2 0.28 In = 91 vs. 0.51 f 
0.38 &ml [n = 81). It is sug&ed;hat u$ fibrosis type 
might possibly be related to the catecholamine level. 
Limit&ions ol this study. Because myocardial fibrosis 
was auantilied with the point-counting melhod in biopsy 
samples, there were some inherent limitations in the biopsy 
study. In terms of the reproducibility of mcasuremcnts by 
the point-counting method, the interobserver variability for 
percent fibrosis was small in this study (4.5 r 2%, n = 6). In 
addition, the determination of the dominant fibrosis type did 
not depend on observers. Another inherent iimitation was 
representativeness of the whole myoxardium in endomyo- 
cardiat biopsy samples. The morphologic changes in the 
myocardium were more or less uniformly distributed over 
the enlire myocardium in patients with dilated cardiomyop 
athy (23,261, although there might be some focal processes 
that could affect our quantitative analysis. However, it is 
evident that the effectiveness of long-term beta.blocler 
therapy could be related lo the myoeardial fibrosis content in 
palienls with dilated cardiomyopathy despite these Ii&a- 
dons. In addition, this is a retrospective study. Accordingly, 
another prospective trial using an external sample will be 
needed to verify our results. 
Con+lusioas. This study showed that the tiectiveners of 
long-term hem-blocker therapy in patients whh dilated car- 
diomyopathy can be predicted from the histologic findings 
such as the severity and the dominant type of fibrosis in 
endomyoczrdial biopsy specimens. 
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